Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/111969

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/111969

题名:	Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer
作者:	PY, Wu;PY, Wu;YC, Lin;YC, Lin;黃元勵;HUANG;YUAN-LI;WM, Chen;WM, Chen;CC, Chen;CC, Chen;Lee, H;Lee, H
贡献者:	生物科技學系
日期:	2018-12
上传时间:	2019-09-10 05:31:35 (UTC+0)
摘要:	Prostate cancer (PCa) is the most common noncutaneous cancer in men worldwide. One of its major treatments is androgen deprivation therapy, but PCa frequently relapses as aggressive castration resistant local tumors and distal metastases. Hence, the development of novel agents or treatment modalities for advanced PCa is crucial. Many tumors, including PCa, first metastasize to regional lymph nodes via lymphatic vessels. Recent findings demonstrate that the bioactive lipid lysophosphatidic acid (LPA) promotes PCa progression by regulating vascular endothelial growth factor-C (VEGF-C), a critical mediator of tumor lymphangiogenesis and lymphatic metastasis. Many of the underlying molecular mechanisms of the LPA–VEGF-C axis have been described, revealing potential biomarkers and therapeutic targets that may aid in the diagnosis and treatment of advanced PCa. Herein, we review the literature that illustrates a functional role for LPA signaling in PCa progression. These discoveries may be especially applicable to anti-lymphangiogenic strategies for the prevention and therapy of metastatic PCa. Keywords: LPA, LPA receptor, prostate cancer, VEGF-C, lymphangiogenesis
關聯:	Cancers
显示于类别:	[生物科技學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	393	检视/开启

检视Licence

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....